In September, an FDA panel recommended expanding the use of Gardasil to males ranging in age from nine to 26.
At the time, the cost effectiveness of such a program was unclear.
However, researchers at Harvard University have since conducted an analysis.
The study shows including boys in the vaccine program exceeds "what the U.S. typically considers good value for the money."
Other experts dispute the finding, saying young men also need protection from sexually transmitted diseases.